29 July 2026

TGA clears twice-yearly biologic for severe asthma

3 minute read

Depemokimab has won TGA approval for severe eosinophilic asthma, expanding biologic treatment options for eligible Australians.

This content is for AHPRA registered professionals only.
Login Join Now

End of content

No more pages to load

Email Address

Password

Confirm Password

First Name

Last Name

Full Name LEAVE THIS BLANK

What field do you work in?

Type of University work:

Industry Specialty:

Other:

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

I agree to the Terms and conditions and privacy policy *

Processing...